Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,170.00 Price Target at Argus

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective upped by Argus from $1,060.00 to $1,170.00 in a report published on Tuesday, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the stock. Truist Financial restated a buy rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Evercore ISI started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an outperform rating and a $1,150.00 price target on the stock. Sanford C. Bernstein assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an outperform rating and a $1,125.00 price target on the stock. Bank of America raised their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an underperform rating in a report on Friday, April 12th. Finally, StockNews.com lowered shares of Regeneron Pharmaceuticals from a strong-buy rating to a buy rating in a report on Tuesday, April 30th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of Moderate Buy and a consensus price target of $1,008.96.

Regeneron Pharmaceuticals Trading Up 0.7 %

REGN stock opened at $1,071.19 on Tuesday. The company has a market capitalization of $118.03 billion, a PE ratio of 31.65, a price-to-earnings-growth ratio of 2.18 and a beta of 0.13. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. Regeneron Pharmaceuticals has a 52 week low of $684.80 and a 52 week high of $1,081.17. The company’s 50-day simple moving average is $974.69 and its 200 day simple moving average is $947.43.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The firm had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 37.12 earnings per share for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,172 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Bonnie L. Bassler sold 756 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the sale, the director now directly owns 1,382 shares in the company, valued at approximately $1,467,684. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael S. Brown sold 1,172 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the sale, the director now owns 1,382 shares in the company, valued at $1,347,256.52. The disclosure for this sale can be found here. Insiders have sold 61,971 shares of company stock valued at $61,217,654 in the last three months. 7.48% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently made changes to their positions in REGN. West Paces Advisors Inc. raised its stake in shares of Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 23 shares during the period. Crewe Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $28,000. Fortitude Family Office LLC bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at about $31,000. MCF Advisors LLC raised its stake in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 12 shares during the period. Finally, Criterion Capital Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at about $37,000. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.